Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis

Abstract We report a patient who was being treated with rituximab for rheumatoid arthritis who developed Babesia microti infection that persisted for 26 months despite prolonged anti-babesia drug therapy. The explanation for the persistence was likely to have been the long-term immunocompromising ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diagnostic microbiology and infectious disease 2016-06, Vol.85 (2), p.231-232
Hauptverfasser:	Raffalli, John, Wormser, Gary P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - drug therapy Babesia microti Babesia microti - isolation & purification Babesiosis Babesiosis - diagnosis Female Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Infectious Disease Internal Medicine Middle Aged Rituximab Rituximab - administration & dosage Rituximab - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract We report a patient who was being treated with rituximab for rheumatoid arthritis who developed Babesia microti infection that persisted for 26 months despite prolonged anti-babesia drug therapy. The explanation for the persistence was likely to have been the long-term immunocompromising effects of rituximab, as evidenced by seronegativity for B. microti antibodies that lasted for more than 1 year after onset of infection.
ISSN:	0732-8893 1879-0070
DOI:	10.1016/j.diagmicrobio.2016.02.016